12 Amendments of Helga STEVENS related to 2016/2057(INI)
Amendment 10 #
Draft opinion
Recital B
Recital B
B. whereas people living with disabilities are the most vulnerable and need medicines the mostfor which there is no treatment/drug yet or people living with rare disabilities are in a particularly parlous position;
Amendment 17 #
Draft opinion
Recital C a (new)
Recital C a (new)
Ca. whereas the Member States all have different basic set-ups for their social security systems and for funding them, and whereas this opinion has no bearing on them;
Amendment 18 #
Draft opinion
Recital C b (new)
Recital C b (new)
Cb. whereas access to drugs, under certain conditions, can be considered to be of general economic interest within the meaning of Article 106(2) TFEU; whereas Treaty rules, in particular competition rules, can accordingly be disapplied in so far as is necessary to achieve the objective pursued;
Amendment 20 #
Draft opinion
Paragraph 1
Paragraph 1
1. Stresses the importance of observing the principle of subsidiarity, as each Member State must address any shortcom; takes the view, however, that better access to medicinges on the basis of its own particular requirementcan be achieved through better cooperation between Member States;
Amendment 28 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Calls for EU incentives so as to prompt governments to negotiate jointly with pharmaceuticals - instead of each going it alone - in order to arrive at better prices;
Amendment 34 #
Draft opinion
Paragraph 2
Paragraph 2
2. Calls for support for the progress achieved by the pharmaceutical industry, hitherto driven by European SMEs too, which have transformed the standard of healthcare in Europe and helped to prolong life expectancy;
Amendment 43 #
Draft opinion
Paragraph 3
Paragraph 3
3. Recommends that each Member State should be free to set its own innovation policy in the field of cutting- edge technologies, possibly with the aid of EU fundingPoints out that innovation policy is conducted at Member State level; underlines the importance nonetheless of the EU's supportive and coordinating role; strongly believes that international cooperation and information sharing should be encouraged;
Amendment 49 #
Draft opinion
Paragraph 3 a (new)
Paragraph 3 a (new)
3a. Takes the view that the development of an international tool for assessing the efficiency/effectiveness of medicines would be a major advance; calls on the EU to promote the importance of scientific evidence that is freed of all political considerations;
Amendment 53 #
Draft opinion
Paragraph 4
Paragraph 4
4. RecommendsPoints out that information sharing and thehigh-quality training ofor medical professionals be madeis an immediate priority; stresses that it is also very important to 'train' patients as regards prevention and get them to take that on board;
Amendment 60 #
Draft opinion
Paragraph 5
Paragraph 5
5. UrgStresses that universal access to medicines should not be contingent on price, which should reflect a fair balancea fair balance must be sought between the cost of research, industry growth and the need for sustainable welfare systems;
Amendment 69 #
Draft opinion
Paragraph 6
Paragraph 6
6. Reiterates that the stability of European welfare systems, which are one of the cornerstones of EU cooperation and whose budgets differ greatly from one Member State to another, is contingent on people being in employment, and that high levels of unemployment are making it essential to find new means of funding welfareTakes the view that welfare systems must not be contingent solely on people being in employment, but, rather, that they must be funded from other revenue sources;
Amendment 73 #
Draft opinion
Paragraph 7
Paragraph 7